Glioblastoma multiform (GBM) is one of the most lethal brain tumors with reduced life expectancy even after surgery and chemoradiotherapy. Some studies investigate different markers to find a relation with therapy and eventually survival. The aim of this study is to investigate the pattern of immunohistochemical expression of mutant isocitrate dehydrogenases (IDH)1, CD133, and β-catenin in GBM and its relation to patient survival.
This retrospective study was done on 97 GBM tissue samples with the construction of three tissue microarray blocks, and immunohistochemistry for mutant IDH1, CD133, and β-catenin were done.
Mutant IDH1 expression was observed in 14 out of 97 GBM samples (14.4%). Patients with mutant IDH expression had significantly longer progression-free survival (PFS) with a median of 12 versus 9 months (P=0.002) and overall survival (OS) with a median of 16 versus 11 months (P<0.001). CD133 was expressed in 19 GBM samples (19.6%) with significantly shorter PFS with 5 months as median versus 10 months (P=0.014) and shorter OS with median of 8 versus 13 months (P<0.001). β-Catenin expression was identified in 60 studied samples (61.9%). Patients with positive expression had shorter PFS with median of 7 versus 12 months (P=0.031) and shorter OS with a median 10 versus 15 months (P=0.028). Furthermore, a significant positive correlation was found between CD133 and β-catenin (P<0.001).
Mutant IDH1 was considered as a good prognostic marker with enhanced survival, whereas CD133 and β-catenin were considered as poor prognostic markers in GBM with strong correlation between both.
Departments of aPathology
bClinical Oncology and Nuclear Medicine
cNeurosurgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Correspondence to Azza Abdel-Aziz, MD, Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt Tel: +20 100 583 8904; e-mails: email@example.com, firstname.lastname@example.org
Received November 27, 2017
Accepted December 19, 2017